Evaluating the effectiveness of different treatments of uterine infections in female camels (Camelus dromedarius).
A total of 480 female camels with a history of conception failure were examined through transrectal palpation, ultrasonography, and vaginal exploration. Animals were categorized according to parity (nulliparous n=200 vs. multiparous n=280), and type of uterine infection (endometritis n=360 vs. metritis n=120). They were randomly assigned to receive one of three intrauterine treatments: (i) 100mL acriflavin 0.1% (group 1, n=170), (ii) 100mL lotagen 4% (group 2, n=200), or (iii) 300mg/100mL gentamicin sulphate (group 3, n=110). All groups received 500microg cloprostenol IM at infusion. Animals were exposed for breeding 7 d later and received 5000 IU hCG im at mating. The criteria for efficacy of treatment were 90 days non-return rate (90 d NRR) and calving rate (CR). The results showed that the 90 d NRR and CR were significantly influenced by parity, type of uterine infection, regime of treatment, and their interactions, P<0.05. Treatment regimes were approximately equally efficient in treating females with endometritis (90 d NRR were 64%, 53.1% and 53.3% and CR were 58.9%, 49.3%, and 42.5% for groups 1, 2, and 3, respectively, P>0.05). In contrast, regimes differed in treating those with metritis (90 d NRR were 55.6%, 75%, and 28.6% and CR were 31.6%, 54.8%, and 12.5% for groups 1, 2, and 3, respectively, P<0.05). In conclusion, a regime consisted of intrauterine lotagen infusion and administration of PGF(2)alpha at infusion and hCG at mating was more efficient for treating female camels with metritis.
Ali
A
A
Department of Veterinary Medicine, College of Agriculture and Veterinary Medicine, Qassim University, Buraydah, Qassim, Saudi Arabia. ahmedali77@hotmail.com
Al-Sobayil
F A
FA
Al-Hawas
A
A
D000167:Acriflavine / Q000627:therapeutic use; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002162:Camelus; D003008:Cloprostenol / Q000627:therapeutic use; D003408:Cresols / Q000627:therapeutic use; D004338:Drug Combinations; D004716:Endometritis / Q000188:drug therapy / Q000662:veterinary; D005260:Female; D005557:Formaldehyde / Q000627:therapeutic use; D005839:Gentamicins / Q000627:therapeutic use; D007239:Infections / Q000188:drug therapy / Q000662:veterinary*; D007247:Infertility, Female / Q000209:etiology / Q000662:veterinary; D010298:Parity; D011247:Pregnancy; D016896:Treatment Outcome; D014591:Uterine Diseases / Q000150:complications / Q000188:drug therapy / Q000662:veterinary*; D014599:Uterus / Q000187:drug effects
D000890:Anti-Infective Agents; D003408:Cresols; D004338:Drug Combinations; D005839:Gentamicins; D005557:Formaldehyde; D000167:Acriflavine; D003008:Cloprostenol; C001716:formaldehyde, meta-cresolsulfonic acid drug combination